Alamar Biosciences Launches NULISAseq™ Neuro 220 Panel, its largest precision proteomics panel with the sensitivity and specificity to advance neurological disease research

Alamar Biosciences, Inc. (“Alamar”), a leader in precision proteomics dedicated to advancing the early detection of disease, is proud to announce the launch of the NULISAseq Neuro 220 Panel with ...
ascopubs.org

Sensitivity and specificity of 61 commercial disease detection products: A systematic review and meta-analysis of 80 cohorts with approximately 445,000 enrolled samples.

Effects of common nutraceutical supplements marketed for cancer prevention on tumor cell growth.
ascopubs.org

Improving the Sensitivity-Specificity Balance of Human Papillomavirus Testing on Self- and Clinician-Collected Samples in South Africa

Women living with and without HIV, age 30-65 years, were recruited in South Africa. Self-collected vaginal samples and clinician-collected cervical samples were tested with Xpert HPV, an assay that ...

Alamar Biosciences, Inc.: Alamar Biosciences Launches NULISAseq Neuro 220 Panel, its largest precision proteomics panel with the sensitivity and specificity to advance ...

New panel expands coverage for Alzheimer's and Parkinson's diseases including 15 new biomarkers developed with support from The Michael J. Fox Foundation for Parkinson's Research (MJFF) and 12 assays ...